Updates are available Correction dated 2025-07-01
Click to view Correction: https://doi.org/10.1038/s41586-025-09294-3
-
Authors
Chaves-Perez, Almudena
Millman, Scott E. https://orcid.org/0000-0002-0249-2729
Janaki-Raman, Sudha
Ho, Yu-Jui
Hinterleitner, Clemens
Barthet, Valentin J. A. https://orcid.org/0000-0002-5396-3594
Morris, John P. IV
Barriga, Francisco M. https://orcid.org/0000-0002-0996-7707
Reyes, Jose
Kyaw, Aye https://orcid.org/0000-0003-0124-0404
Pasolli, H. Amalia https://orcid.org/0000-0003-3899-3530
Pe’er, Dana https://orcid.org/0000-0002-9259-8817
Thompson, Craig B. https://orcid.org/0000-0003-3580-2751
Finley, Lydia W. S. https://orcid.org/0000-0003-4023-7574
Cross, Justin R. https://orcid.org/0000-0002-6356-057X
Lowe, Scott W. https://orcid.org/0000-0002-5284-9650
- License Information
-
More Information
Article History
Received: 27 June 2023
Accepted: 2 May 2025
First Online: 11 June 2025
Change Date: 1 July 2025
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41586-025-09294-3
Competing interests
: A patent application (PCT/US2024/027206) has been published as WO2024229094A1 (; ref. 50). The patent covers methods for treating gastrointestinal inflammatory diseases using αKG modulators. A.C.-P. and S.W.L. are listed as inventors. S.W.L. is a founder and member of the scientific advisory board of Blueprint Medicines, Mirimus, ORIC Pharmaceuticals, Senescea, and Faeth Therapeutics, is on the scientific advisory board of PMV Pharmaceuticals and is a consultant for Fate Therapeutics. The remaining authors declare no competing interests.
